Mutation News and Research

RSS

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

University of Utah researchers knock out genes in nematode worms

Knocking genes out of action allows researchers to learn what genes do by seeing what goes wrong without them. University of Utah biologists pioneered the field. Mario Capecchi won a Nobel Prize for developing knockout mice. Kent Golic found a way to cripple fruit fly genes. Now, biologist Erik Jorgensen and colleagues have devised a procedure for knocking out genes in nematode worms.

26 Apr 2010

FDA clears Osmetech's eSensor Thrombophilia Risk Test

Osmetech, plc today announced that the US Food and Drug Administration (FDA) has cleared the eSensor® Thrombophilia Risk Test (TRT), a multiplexed molecular diagnostic test for four genetic markers associated with thrombosis. The panel includes Factor V Leiden, Factor II Prothrombin, MTHFR 677 and MTHFR 1298 in a single test panel.

26 Apr 2010

Genes that predispose to smoking behavior and lung cancer identified: More reason to quit say researchers

According to new research there are certain genes in a smoker that make it difficult for them to cut down or quit the bad habit. This report from three studies published in the journal Nature Genetics mentions at least three different genetic mutations on chromosome 15 or changes that can increase the number of cigarettes smoked per day by an individual.

25 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

Recent business progress at Penwest Pharmaceuticals

Penwest Pharmaceuticals Co. today sent a letter to its shareholders to provide an update on the Company's recent progress and on corporate governance developments.

24 Apr 2010

Temperature-sensing ability in proteins remain a mystery

Scientists at The Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation (GNF) have shed new light on the molecular mechanism that enables us to sense temperature, such as the heat from a sizzling stove. In addition to contributing to our knowledge of basic biology, the findings could one day lead to new therapies for conditions such as acute or chronic inflammatory pain.

24 Apr 2010

New understanding of nerve cell influence in exchange of information

Nerve cells communicate with each other by means of electrical impulses. To create such an impulse, the cells exchange charged ions with their environment. However, the role played by the ever-present chloride channels remained obscure, although some theories predicted a relation between the chloride channel ClC-2 and epilepsy.

24 Apr 2010

Moffitt Cancer Center reports increasing interest in ERCC1 Analysis test for selecting chemotherapy for NSCLC

24 Apr 2010

Environmental factors may play bigger role in tumor development: BIDMC study

It is an accepted fact that genetics play a key role in a person's susceptibility to cancer, and that throughout life, mutations can cause damage to tumor suppressor genes further increasing the chances of developing cancerous tumors.

24 Apr 2010

GIS scientists' zebrafish model may aid drug development for PD

Scientists at the Genome Institute of Singapore, a biomedical research institute of the Agency for Science, Technology and Research, have recently developed a zebrafish model for Parkinson's disease that can be used for understanding the mechanism underlying its development. The knowledge gained will be helpful for future screening of new drugs to treat Parkinson's disease.

23 Apr 2010

Crystal structures of key fluorescent proteins to "light up" molecules in cells

Scientists at Albert Einstein College of Medicine of Yeshiva University have determined the crystal structures of two key fluorescent proteins - one blue, one red - used to "light up" molecules in cells.

23 Apr 2010

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

Deadly fungus on the move

Researchers revealed this Thursday that a deadly fungus that is usually found only in the tropics is making its way to the Pacific Coast of British Columbia and south into Washington, Oregon and Idaho.

23 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010